Resultados da pesquisa - (( j la compra can near ) OR ((( 5 tail complex can new ) OR ( a small companies _ now ))))

Pesquisas alternativas:
tail » tal (Expandir a Pesquisa)

1

Cholera toxin inhibits SNX27-retromer-mediated delivery of cargo proteins to the plasma membrane

Cholera toxin inhibits SNX27-retromer-mediated delivery of cargo proteins to the plasma membrane

Por Singh, Varsha, Yang, Jianbo, Yin, Jianyi, Cole, Robert, Tse, Ming, Berman, Diego E., Small, Scott A., Petsko, Gregory, Donowitz, Mark
Publicado no J Cell Sci (2018)

“...Cholera toxin (CT) causes severe diarrhea by increasing intracellular cAMP leading to a PKA...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

2

CRITERIA FOR ASSESSMENT OF ANTICORRUPTION COMPLIANCE PROGRAMS AT SMALL AND MEDIUM ENTERPRISES

CRITERIA FOR ASSESSMENT OF ANTICORRUPTION COMPLIANCE PROGRAMS AT SMALL AND MEDIUM ENTERPRISES

Por G. Crouse, L. A. Chaldaeva, A. A. Kilyachkov
Publicado em 2017-10-01

Assuntos: “...small and medium-sized enterprises (sme)...”
Obter o texto integral

Artigo

3

Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer

Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer

Por Randall, J. Michael, Bharne, Anjali A., Bazhenova, Lyudmila A.
Publicado em 2013

“... patients. Now that adjuvant chemotherapy is a component of NSCLC treatment, platinum hypersensitivity...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

4

Transformation of the operational reporting the companies on the basis of approach Business Intelligence

Transformation of the operational reporting the companies on the basis of approach Business Intelligence

Por V. M. Kornev, O. V. Bakanach, Y. A. Tokarev, D. S. Danilin
Publicado em 2017-02-01

“... of processes of preparation of the analytical reporting in the growing companies now. The organization...”
Obter o texto integral

Artigo

5

License Compliance Issues For Biopharmaceuticals: Special Challenges For Negotiations Between Companies And Non-Profit Research Institutions

License Compliance Issues For Biopharmaceuticals: Special Challenges For Negotiations Between Companies And Non-Profit Research Institutions

Por Ponzio, Todd A., Feindt, Hans, Ferguson, Steven
Publicado em 2011

“... by regulatory requirements, that must be met to bring a new drug to market, such as completion of preclinical...”
Obter o texto integral
Obter o texto integral

Artigo

6

Treatment for small cell lung cancer, where are we now?—a review

Treatment for small cell lung cancer, where are we now?—a review

Por Alvarado-Luna, Gabriela, Morales-Espinosa, Daniela
Publicado no Transl Lung Cancer Res (2016)

Assuntos: “...Review Article on Small Cell Lung Cancer...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

7

Is chest radiation now a classical practice for extensive small cell lung cancer?

Is chest radiation now a classical practice for extensive small cell lung cancer?

Por Van Houtte, Paul, Moretti, Luigi, Roelandts, Martine
Publicado no Transl Lung Cancer Res (2015)

“... radiation showing a benefit mainly in local control. A critical analysis of this trial point out all...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

8

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Por Chan, Bryan A., Hughes, Brett G.M.
Publicado no Transl Lung Cancer Res (2015)

“...In recent years, there has been a major paradigm shift in the management of non-small cell lung...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

9

Active-specific immunotherapy for non-small cell lung cancer

Active-specific immunotherapy for non-small cell lung cancer

Por Winter, Hauke, van den Engel, Natasja K., Rusan, Margareta, Schupp, Nina, Poehlein, Christian H., Hu, Hong-Ming, Hatz, Rudolf A., Urba, Walter J., Jauch, Karl-Walter, Fox, Bernard A., Rüttinger, Dominik
Publicado em 2011

“...Non-small cell lung cancer constitutes about 85% of all newly diagnosed cases of lung cancer...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

10

The rate of return of the primary offerings on the example of small firms listed on the NewConnect and companies on the WSE main maret

The rate of return of the primary offerings on the example of small firms listed on the NewConnect and companies on the WSE main maret

Por Marcin Jan Flotyński
Publicado em 2015-01-01

Assuntos: “...NewConnect...”
Obter o texto integral

Artigo

11

The internal control of tax

The internal control of tax

Por E. B. Shuvalova, L. A. Butenko, Ju. A. Rudenko
Publicado em 2016-10-01

“... scientific basis and practical recommendations for the application. This difficult task is now solved only...”
Obter o texto integral

Artigo

12

The world of children in the capital of Tuva

The world of children in the capital of Tuva

Por Vladimir A. Kisel
Publicado em 2016-02-01

“... art and small outdoor statuary. In 2003 the federal Cabinet adopted a new state standard, which set...”
Obter o texto integral

Artigo

13

Big Data for Qualitative Research

Big Data for Qualitative Research

Por Mills, Kathy A.
Publicado em 2019

Assuntos: “...bic Book Industry Communication::J Society & social sciences::JM Psychology::JMB Psychological...”
Obter o texto integral

Livro

14

Recurrent Dislocation of the Shoulder Joint: Anthony F. DePalma MD

Recurrent Dislocation of the Shoulder Joint: Anthony F. DePalma MD

Por Brand, Richard A.
Publicado em 2008

“... was finalized in 1951, and Drs. DePalma and McBride signed a contract with J.B. Lippincott Company. Dr. DePalma...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

15

Biophysical rhizosphere processes affecting root water uptake

Biophysical rhizosphere processes affecting root water uptake

Por Carminati, A., Zarebanadkouki, M., Kroener, E., Ahmed, M. A., Holz, M.
Publicado no Ann Bot (2016)

“...Background Recent advances in imaging techniques now make it possible to visualize...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

16

Case series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancer

Case series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancer

Por Britt, Gregory J, Gaughan, Elizabeth M, Nguyen, Kim-Son H, Warner, Jeremy L, Goldstein, Michael A, Huberman, Mark S, Costa, Daniel B
Publicado em 2011

“...An increasing number of nonagenarians are treated for non-small-cell lung cancer (NSCLC); however...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

17

RNAs that make a heart beat

RNAs that make a heart beat

Por Mitra, Mithun, Coller, Hilary A.
Publicado no Ann Transl Med (2016)

“...-223-3p, can regulate a component of the voltage-gated channel that mediates rapid outward efflux...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

18

Drones for Biodiversity Conservation and Ecological Monitoring

Drones for Biodiversity Conservation and Ecological Monitoring

Por Mücher, C.A., Díaz-Delgado, Ricardo
Publicado em 2019

Assuntos: “...small UAV...”
Obter o texto integral

Livro

19

Appropriate screening intervals in low-dose CT lung cancer screening

Appropriate screening intervals in low-dose CT lung cancer screening

Por Heuvelmans, Marjolein A., Oudkerk, Matthijs
Publicado no Transl Lung Cancer Res (2018)

“... 1 and 2 years until their risk profile changes. In case a new pulmonary nodule appears at subsequent...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

20

Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?

Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?

Por Ou, Sai-Hong Ignatius, Soo, Ross A., Kubo, Akihito, Kawaguchi, Tomoya, Ahn, Myung-Ju
Publicado em 2014

“... by the company seeking the first drug approval in a new indication. Given the low incidence of ROS1-rearrangement...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

1
2
3
4
5
6
7
8
9
10
11
Seguinte
[16]